698 related articles for article (PubMed ID: 24979544)
1. New and emerging therapies in psoriasis.
Leonardi CL; Gordon KB
Semin Cutan Med Surg; 2014 Mar; 33(2 Suppl 2):S37-41. PubMed ID: 24979544
[TBL] [Abstract][Full Text] [Related]
2. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.
Bilal J; Berlinberg A; Bhattacharjee S; Trost J; Riaz IB; Kurtzman DJB
J Dermatolog Treat; 2018 Sep; 29(6):569-578. PubMed ID: 29532693
[TBL] [Abstract][Full Text] [Related]
3. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab.
Tausend W; Downing C; Tyring S
J Cutan Med Surg; 2014; 18(3):156-69. PubMed ID: 24800703
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of emerging immunotherapies in psoriasis.
Yiu ZZ; Warren RB
Immunotherapy; 2015; 7(2):119-33. PubMed ID: 25713988
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.
Jeon C; Sekhon S; Yan D; Afifi L; Nakamura M; Bhutani T
Hum Vaccin Immunother; 2017 Oct; 13(10):2247-2259. PubMed ID: 28825875
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic development in psoriasis.
Sobell JM; Leonardi CL
Semin Cutan Med Surg; 2014 Jun; 33(4 Suppl):S69-72. PubMed ID: 25268599
[TBL] [Abstract][Full Text] [Related]
7. [New biological drugs in the treatment of inflammatory skin diseases].
Mälkönen T
Duodecim; 2014; 130(6):627-34. PubMed ID: 24724461
[TBL] [Abstract][Full Text] [Related]
8. Biologics for Psoriasis.
Wride AM; Chen GF; Spaulding SL; Tkachenko E; Cohen JM
Dermatol Clin; 2024 Jul; 42(3):339-355. PubMed ID: 38796266
[TBL] [Abstract][Full Text] [Related]
9. Safety of biologics in psoriasis.
Kamata M; Tada Y
J Dermatol; 2018 Mar; 45(3):279-286. PubMed ID: 29226369
[TBL] [Abstract][Full Text] [Related]
10. Biologic Therapy in Psoriasis (Part II): Efficacy and Safety of New Treatment Targeting IL23/IL-17 Pathways.
Molinelli E; Campanati A; Brisigotti V; Offidani A
Curr Pharm Biotechnol; 2017; 18(12):964-978. PubMed ID: 29299984
[TBL] [Abstract][Full Text] [Related]
11. New biologics in psoriasis: an update on IL-23 and IL-17 inhibitors.
Dong J; Goldenberg G
Cutis; 2017 Feb; 99(2):123-127. PubMed ID: 28319618
[TBL] [Abstract][Full Text] [Related]
12. The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.
AbuHilal M; Walsh S; Shear N
J Cutan Med Surg; 2016 Nov; 20(6):509-516. PubMed ID: 27207350
[TBL] [Abstract][Full Text] [Related]
13. Anti-interleukin-17 treatment of psoriasis.
Jinna S; Strober B
J Dermatolog Treat; 2016 Aug; 27(4):311-5. PubMed ID: 26943806
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents.
Gan EY; Chong WS; Tey HL
BioDrugs; 2013 Aug; 27(4):359-73. PubMed ID: 23580094
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis.
Mease PJ
Curr Opin Rheumatol; 2015 Mar; 27(2):127-33. PubMed ID: 25599143
[TBL] [Abstract][Full Text] [Related]
16. Update on New and Emerging Therapies in the Management of Psoriasis.
Gordon KB
Semin Cutan Med Surg; 2015 Mar; 34(2 Suppl):S34-6. PubMed ID: 26623549
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-17 (IL-17) inhibitors in the treatment of plaque psoriasis: a review.
Gooderham M; Posso-De Los Rios CJ; Rubio-Gomez GA; Papp K
Skin Therapy Lett; 2015; 20(1):1-5. PubMed ID: 25807214
[TBL] [Abstract][Full Text] [Related]
18. Anti-IL-17 phase II data for psoriasis: A review.
Brown G; Malakouti M; Wang E; Koo JY; Levin E
J Dermatolog Treat; 2015 Feb; 26(1):32-6. PubMed ID: 24552447
[TBL] [Abstract][Full Text] [Related]
19. Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis.
Egeberg A; Andersen YMF; Halling-Overgaard AS; Alignahi F; Thyssen JP; Burge R; Mallbris L
J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):39-46. PubMed ID: 31465593
[TBL] [Abstract][Full Text] [Related]
20. Gut Microbiome in Psoriasis is Perturbed Differently During Secukinumab and Ustekinumab Therapy and Associated with Response to Treatment.
Yeh NL; Hsu CY; Tsai TF; Chiu HY
Clin Drug Investig; 2019 Dec; 39(12):1195-1203. PubMed ID: 31549347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
